We report the cloning of a novel PDGFRB fusion gene partner in a patient with a chronic myeloproliferative disorder characterized by t(5;14)(q33;q32), who responded to treatment with imatinib mesylate. Fluorescence in situ hybridization demonstrated that PDGFRB was involved in the translocation. Long distance inversion PCR identified KIAA1509 as the PDGFRB fusion partner. KIAA1509 is an uncharacterized gene with a predicted coiled-coil oligomerization domain with homology to the HOOK family of proteins. The predicted KIAA1509-PDGFRb fusion protein contains the KIAA1509 coiled-coil domain fused to the cytoplasmic domain of PDGFRb that includes the tyrosine kinase domain. Imatinib therapy resulted in rapid normalization of the patient's blood counts, and subsequent bone marrow biopsies and karyotypic analysis were consistent with sustained complete remission.
Introduction
Fusion genes that result in constitutive activation of tyrosine kinases characterize a subset of chronic myeloproliferative disorders. These fusion genes are the result of chromosomal translocations or interstitial deletions.
1,2 In chronic myelomonocytic leukemia (CMML), a subset of patients have balanced translocations involving the platelet-derived growth factor receptor beta (PDGFRB) gene. To date, eight PDGFRB fusion partners (ETV6, CEV14, HIP1, H4/D10S170, RABEP1, Myomegalin/PDE4DIP, NIN, and HCMOGT-1) have been identified. [3] [4] [5] [6] [7] [8] [9] [10] In each case, chromosomal translocation results in fusion of the 3 0 region of PDGFRB encoding the kinase domain to a 5 0 fusion partner with a putative oligomerization domain. It has been demonstrated in most of these that the PDGFRb tyrosine kinase is constitutively activated as a consequence of fusion to a dimerization or oligomerization motif in the amino-terminal partner. For example, fusion of the ETV6 PNT oligomerization domain to PDGFRb results in self-association and constitutive tyrosine kinase activity, and both the oligomerization and kinase domains are required for transformation of hematopoetic cells.
11
Mice engineered to express the ETV6-PDGFRb fusion protein using a lymphoid-specific promoter developed T and B cell lymphomas, and treatment with imatinib results in prolonged survival in these mice. 11, 12 There are additional reports of translocations involving PDGFRB in MPDs where the fusion partner is not yet known. 13 Imatinib mesylate (Gleevec; Novartis, Basel, Switzerland) is a specific tyrosine kinase inhibitor with clinical activity in chronic myelogenous leukemia, hypereosinophilic syndrome, and gastrointestinal stromal tumors.
2,14,15 Based on the observation that imatinib inhibits the growth of ETV6-PDGFRB transformed cells, imatinib has been administered to three CMML patients with the ETV6-PDGFRB fusion; durable responses were seen in all three cases. 16 Similar responses to imatinib have been reported in patients with the PDE4DIP-PDGFRB and NIN-PDGFRB fusion genes, and in a patient with the RABEP1-PDGFRB fusion gene with a molecular relapse after allogeneic bone marrow transplantation. 8, 9, 17 In this report we describe a patient with a myeloproliferative disorder characterized by the chromosomal abnormality t(5;14)(q33;q32). The consequence of the chromosomal translocation is fusion of the coiled-coil domain of KIAA1509 to the tyrosine kinase domain of PDGFRb. Imatinib therapy resulted in a rapid, complete, and durable hematologic and cytogenetic response.
Materials and methods

Study design
In July 2002, a 42-year-old man was incidentally noted to have a white blood cell count of 64 900/ml with 41% bands, 21% neutrophils, 7% lymphocytes, 5% eosinophils, 12% monocytes, and 4% metamyelocytes. His platelet count was 176 000/ml and his hemoglobin was 9.0 g/dl. Physical examination revealed no lymphadenopathy or splenomegaly. Bone marrow biopsy revealed a hypercellular marrow with granulocytic hyperplasia. Cytogenetic analysis revealed t(5;14)(q31;q32) in 14 of 16 metaphases analyzed and inv(9)(p23;q13) in all metaphases analyzed. The BCR-ABL fusion gene was not detected. The patient was enrolled in a clinical trial using imatinib mesylate in patients with CMML, which was defined as a t(9;22) negative myeloproliferative disorder associated with a peripheral blood monocytosis greater than 1000/ml. Patients on this trial were treated with a daily oral dose of 400 mg imatinib and were monitored with weekly blood counts and bone marrow examinations every 3 months.
Fluorescence in situ hybridization
Fluorescence in situ hybridization (FISH) was performed as described previously. 18 Cosmid probes c4-6, c4-1, and c12
spanning the PDGFRB gene were kindly provided by Dr M Dixon (University of Manchester, Manchester, UK).
Molecular cloning of the genomic breakpoint
Rapid amplification of cDNA ends (RACE) was performed as previously described. 19 Long distance inversion PCR (LDI-PCR) was performed as previously described. 20 EcoRV was chosen for digestion based on the identification of a single EcoRV restriction site within the kinase domain of the PDGFRB gene without additional restriction sites within 10Kb of upstream genomic sequence. LDI-PCR was performed using primers PDGFRB-LDI1 (5 0 cctcaatgctaggcagttcc) and PDGFRB-RV1 (5 0 -ctgtggccaactgggtctat) in the first PCR and PDGFRB-LDI2 (5 0 ccaacttgagtccccacact) and PDGFRB-RV2 (5 0 tcctcagcattat gcaacca) in the nested PCR. The sequence of the LDI-PCR product was analyzed using the BLAST program (http:// www.ncbi.nlm.nih.gov/BLAST). The genomic breakpoint was amplified from patient DNA using primers KIAA1509-F3 (5 0 -cttatttgggatggagccct) and PDGFRB-R1 (5 0 -accaggtagggtact cggct). The fusion transcript was amplified using primers KIAA1509-RTF1 (5 0 -ccgggacacagataaga) and PDGFRB-RTR1 (5 0 -catgatcttcagctccgaca).
Results and discussion
Response to imatinib
The patient initiated treatment with imatinib in October 2002; by that time his white blood cell count had increased to 168 000/ml, his spun hematocrit had decreased to 25%, and his platelet count was 178 000/ml. After 1 month of therapy, he was in a hematologic remission with a normal complete blood count and differential (Figure 1 ). After 3 months of therapy a bone marrow biopsy showed a hypocellular marrow with one focus of hypercellularity and fibrosis. Cytogenetic analysis did not identify the t(5;14)(q33;q32) in any cells analyzed, though inv(9)(p23;q13) was again identified in all cells analyzed, suggesting a constitutional origin of inv (9) . At 18 months of follow-up, the patient remains in a cytogenetic remission; his most recent bone marrow examination revealed a normocellular marrow with a normal myeloid to erythroid ratio. He has tolerated therapy well with only grade 1 periorbital edema, and he continues on imatinib 400 mg daily.
Molecular cloning of the t(5;14)(q33;q32)
FISH analysis (Figure 2 ) confirmed that the breakpoint involved the PDGFRB locus. Initial attempts to identify the fusion partner using RACE were unsuccessful, presumably due to a paucity of RNA. We then used LDI-PCR to amplify the translocation breakpoint in genomic DNA. A 3Kb PCR product was identified, and sequence analysis of this PCR product revealed a fusion between intron 9 of KIAA1509 and intron 10 of PDGFRB. The fusion was confirmed by PCR on patient DNA and RNA (Figure 3 ). KIAA1509 is a predicted gene (XM_029353) located on chromosome band 14q32, and a partial cDNA has been cloned in a large-scale cloning project. 21 Based on data from GeneNote (http://genecards.weizmann.ac.il/cgi-bin/genenote/home_page/ pl) KIAA1509 is widely expressed, with highest levels of expression in bone marrow, spleen and thymus. The predicted mRNA encodes a 1935 amino-acid protein with 73% aminoacid homology to the mouse 0610010D24Rik (Daple) protein.
Daple was identified based on its interaction with Dvl, and Daple has been shown to inhibit Wnt-3a-dependent accumulation of b-catenin.
22
The in-frame fusion transcript encodes a 934 amino-acid protein composed of the N-terminal 355 amino acids of the putative KIAA1509 protein and the C-terminal 579 amino acids of PDGFRb (Figure 3 ). There is 45% homology between the Nterminal region of KIAA1509 and the central coiled coil domain of the HOOK family of proteins. 23 The coiled coil domain is highly conserved between the Drosophila hook protein and the human HOOK proteins, and the Drosophila hook coiled coil domain mediates dimerization. 24 Analysis using the pepcoil program (http://www.emboss.org/) suggests there is a 99% 
Figure 1
White blood cell count of patient with t(5;14)(q33;q32) before and after initiation of imatinib therapy. The graph shows the patient's total peripheral white blood cell count and percentage of metaphases positive for t(5;14)q33;q32), measured at the time of diagnosis and then subsequently while enrolled in a clinical trial of imatinib therapy in chronic myelomonocytic leukemia. The table specifies the number of positive metaphases and total number of metaphases analyzed for each timepoint where cytogenetic analysis was performed.
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Figure 2
Fluorescence in situ hybridization demonstrates a breakpoint within the PDGFRB locus in a patient with t(5;14)(q33;q32). Three-color FISH analysis with three cosmid probes (c4-6: yellow; c4-1: green; c12-a: red) spanning the PDGFRB gene were used to document a break within PDGFRB.
likelihood of a coiled coil domain within the N-terminal region (residues 128-227) of KIAA1509. It is likely that the coiled coil domain of KIAA1509 mediates homodimerization and constitutive activation of the PDGFRb tyrosine kinase, as has been demonstrated for ETV6-PDGFRb and other PDGFRb fusions.
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The breakpoint within PDGFRB is within intron 10, which is identical to the location of the genomic breakpoints of all known PDGFRB fusion genes except for NIN-PDGFRB. [3] [4] [5] [6] [7] [8] [9] [10] 19 It is therefore likely the LDI-PCR strategy described in this case report can be used to identify novel PDGFRB fusion partners in additional patients, based on the conserved location of translocation breakpoints within PDGFRB.
In summary, we have identified KIAA1509 as a novel fusion partner for PDGFRB in a patient with t(5;14)(q33;q32) and an MPD. Treatment with imatinib resulted in a rapid, complete, and sustained hematologic and cytogenetic response. Like other PDGFRb fusion proteins associated with a CMML phenotype, it is most likely that the KIAA1509-PDGFRb fusion is a constitutively activated tyrosine kinase that is imatinib-sensitive. In support of this hypothesis, imatinib resulted in complete remission in a patient with the t(5;14)(q33;q32). These data provide further evidence that patients with a CMML phenotype and translocations involving the PDGFR locus are good candidates for therapy with imatinib. However, cloning of these chromosomal translocations may be difficult due to lack of RNA and limiting amounts of genomic DNA. Strategies such as LDI-PCR, in conjunction with new methods for whole-genome amplification to expand DNA template, 25 should allow for reliable identification of patients with CMML with PDGFRb rearrangements that may be imatinib responsive. 
